



Hamlet BioPharma secures new patents to develop scientific discoveries into drugs for the treatment of cancer and infections

Hamlet BioPharma, a global leader in the treatment of cancer and infections announces the successful granting of new patents, strengthening its intellectual property portfolio, reaffirming its position at the forefront of technological innovation. Five new patents in Australia, China, India, Japan, and the US have been granted since the press release on 7 April 2025, which announced three new patents.

The newly granted patents cover breakthroughs in the HAMLET family of drug candidates which effectively kill cancer cells and growing tumor tissue with high precision, as well as the company's technology relating to the treatment of infections, including cystitis. Among the most notable is US Patent No. 12,331,073, which introduces a groundbreaking way of manufacturing the HAMLET drugs.

With these latest additions, Hamlet BioPharma now holds over 140 active patents and over 25 pending patent applications across numerous countries, showcasing a robust innovation strategy designed to fuel long-term growth, protect proprietary technologies, and drive value for partners and customers alike.

The company now plans to integrate these patented technologies into upcoming products and services, for use in future clinical trials.

"Innovation is at the heart of everything we do. These patents are not just legal milestones — they're a reflection of our team's commitment to pushing boundaries and delivering real options for the treatment of cancer and infections", comments CEO and Founder Catharina Svanborg.

About Hamlet BioPharma

Hamlet BioPharma is an innovative biotechnology company that develops scientific discoveries into drugs for the treatment of cancer and infections. The goal is to address unmet medical needs in large patient groups in need of improved cancer treatments or alternatives to antibiotics. The company is leveraging highly innovative scientific discoveries and an extensive IP portfolio, to take these innovative drugs through mechanistic and preclinical phases, through the development of drug production technology to the clinic. Three projects in clinical development are in Phase II trials. The company is listed at Spotlight Stockmarket, ticker HAMLET.

For further information, please contact:

Catharina Svanborg, CEO and Founder of Hamlet BioPharma, +46-709 42 65 49,
catharina.svanborg@hamletpharma.com

Ines Ambite, Senior Scientist, Lund University, +46 762 08 89 58, ines.ambite@med.lu.se

www.hamletbiopharma.com